 ceftazidim amikacin versu ceftazidim vancomycin empir therapi febril neutropen children cancer antibiot regimen ceftazidim amikacin ceftazidim vancomycin prospect random clinic trial empir therapi febril granulocytopen children cancer rate respons similar group preval secondari gram-neg bacteremia group vancomycin advers reaction latter group mortal group adjust independ predictor respons treatment mean multivari analysi lack remark differ respons regimen use vancomycin amikacin combin ceftazidim outcom treatment fever infect granulocytopen children cancer use vancomycin increas frequenc secondari infect due gram-neg bacteria advers reaction